US Patent

US9168239 — Levothyroxine formulations

Formulation · Assigned to Fresenius Kabi USA LLC · Expires 2032-08-29 · 6y remaining

Vulnerability score 42/100 Strong — defensible against typical IPR challenges

What this patent protects

This patent protects a lyophilized solid levothyroxine composition that includes levothyroxine sodium and mannitol.

USPTO Abstract

A levothyroxine composition includes levothyroxine sodium and mannitol. The composition is a lyophilized solid. The composition may include from 100 to 500 micrograms levothyroxine sodium and from 2 to 4 milligrams mannitol.

Drugs covered by this patent

Patent Metadata

Patent number
US9168239
Jurisdiction
US
Classification
Formulation
Expires
2032-08-29
Drug substance claim
No
Drug product claim
Yes
Assignee
Fresenius Kabi USA LLC
Source
FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.